HALOZYME THERAPEUTICS, INC.
At today's price, HALOZYME THERAPEUTICS, INC. (HALO) is priced for -4.0% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Halozyme is a royalty machine more than a drug company: its ENHANZE technology lets partners turn intravenous medicines into quick subcutaneous injections, and it earns royalties on ten launched products including DARZALEX SC, Phesgo, and VYVGART Hytrulo, per the FY2025 10-K. • The business is unusually profitable for biotech, running an operating margin near 34% on royalty income, and revenue grew 42% last quarter, yet the stock trades at only about 13 times operating income [Source: Halozyme
Is HALO overvalued? See what's priced in →
615 institutional managers reported holding HALO in 13F filings for the quarter ended 2026-03-31. 84 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 12.9M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (7.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
HALO has cut its share count 17.1% over the past five years, spending $1.42B on repurchases. It pays no dividend. Cash returned over the past three years: $844.67M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at HALO over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
HALO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +1.5% | -12.5% |
| 2023-11-07 | +9.1% | -9.8% |
| 2024-02-21 | +6.3% | +2.0% |
| 2024-05-08 | +2.8% | +26.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
HALO's latest 8-K filings: 2026-07-02 (items 5.02); 2026-05-11 (items 2.02, 9.01); 2026-05-07 (items 5.07); 2026-04-30 (items 5.02, 9.01); 2026-04-24 (items 5.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.